Fig. 4.
Fig. 4. Leukapheresis collections from days 5 plus 6 plus 7 (relative to G-CSF administration) for each patient cohort: G-CSF alone (G-CSF, ▪); SCF 5 μg/kg/d plus G-CSF (SCF 5, ); SCF 10 μg/kg/d plus G-CSF (SCF 10, ▨); SCF 15 μg/kg/d plus G-CSF (SCF 15, ); and SCF pretreatment (SCF pre, □). Results are mean ± SE for d7 GM-CFC (A), d14 GM-CFC (B), BFU-E (C), and CD34+ cells (D). The apparent decrease in GM-CFC collected in Cohort D was interpreted as reflecting the smaller number of patients in this cohort, the wide interindividual variation, and the increased number of patients with stage III disease in this group.

Leukapheresis collections from days 5 plus 6 plus 7 (relative to G-CSF administration) for each patient cohort: G-CSF alone (G-CSF, ▪); SCF 5 μg/kg/d plus G-CSF (SCF 5, ); SCF 10 μg/kg/d plus G-CSF (SCF 10, ▨); SCF 15 μg/kg/d plus G-CSF (SCF 15, ); and SCF pretreatment (SCF pre, □). Results are mean ± SE for d7 GM-CFC (A), d14 GM-CFC (B), BFU-E (C), and CD34+ cells (D). The apparent decrease in GM-CFC collected in Cohort D was interpreted as reflecting the smaller number of patients in this cohort, the wide interindividual variation, and the increased number of patients with stage III disease in this group.

Close Modal

or Create an Account

Close Modal
Close Modal